Literature DB >> 31672039

Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential.

Rupert McShane1, David S Baldwin1, R Hamish McAllister-Williams1, James M Stone1, David Taylor1, Adam R Winstock1, Allan H Young1.   

Abstract

Keywords:  Drugs-New; Ketamine; Research Design And Methods

Mesh：

Substances：

Year:  2019        PMID： 31672039     DOI： 10.1176/appi.ajp.2019.19060631

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  3 in total

1.  Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors:  William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

Review 2.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

3.  Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.

Authors:  Jennifer Swainson; Larry J Klassen; Stefan Brennan; Pratap Chokka; Martin A Katzman; Robert L Tanguay; Atul Khullar
Journal:  CNS Drugs       Date:  2022-02-14       Impact factor: 5.749
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.